Advanced Biomed Inc. 8-K

What Happened

• Advanced Biomed Inc. (ADVB) reported that Nasdaq notified the company it had closed below the $1.00 per‑share minimum bid requirement and was given until January 14, 2026 to regain compliance. After failing to regain compliance by that date, Nasdaq moved to delist and suspend the stock, but the company appealed.
• The company presented a compliance plan — including a reverse stock split approved by shareholders on January 12, 2026 and completed on February 20, 2026 — at a hearing on February 17, 2026. On March 12, 2026, a Nasdaq Listing Qualifications Panel determined ADVB had regained compliance (maintaining a closing bid of $1.00+ after the split). ADVB’s common stock will remain listed, subject to a one‑year Panel monitor under Nasdaq rules.

Key Details

• Nasdaq notice: company failed to meet Nasdaq Listing Rule 5550(a)(2) minimum $1.00 bid; initial compliance period ended January 14, 2026.
• Appeal timeline: delisting notice dated January 16, 2026; company appealed January 21, 2026; hearing held February 17, 2026; Panel decision issued March 12, 2026.
• Reverse split: shareholder approval January 12, 2026; split completed February 20, 2026; Panel found the post‑split closing bid met the $1.00 requirement.
• Result: Nasdaq listing retained, but subject to a one‑year monitor per Nasdaq Listing Rule 5815(d)(4)(A).

Why It Matters

• For investors, the ruling means ADVB shares will continue trading on Nasdaq rather than being delisted, preserving liquidity and access to the market.
• The reverse stock split changed the company’s share count and per‑share price, which affects share ownership proportions and may influence market perception and trading behavior.
• The one‑year Panel monitoring means Nasdaq will closely review the company’s continued compliance; failure to maintain requirements could lead to renewed delisting risk.